Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Boehringer partners with Simcere to develop a bispecific antibody that simultaneously inhibits two drivers of inflammatory bowel disease....

Read Full Article →